载体订购信息

产品编号
GS-1059
产品名称
pIRESneo 哺乳动物表达载体
市场价格
¥ 1000
沟通洽谈

载体基本信息

载体名称:
pIRESneo
载体类型:
哺乳动物表达载体
克隆方法:
/
拷贝类型:
载体抗性:
Ampicillin (氨苄青霉素)
筛选标记:
Neomycin (新霉素)
载体大小:
/
启动子:
CMV IE
测序引物5’:
CMV-F: 5'-CGCAAATGGGCGGTAGGCGTG-3'
测序引物3’:
/
报告基因:
/

载体图谱展示

载体图谱

载体说明

pIRESneo (originally described as pCIN4 by Rees et al.; 1) contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV), which permits the translation of two open reading frames from one messenger RNA (2, 3). After selection with G418, nearly all surviving colonies will stably express the gene of interest, thus decreasing the need to screen large numbers of colonies to find functional clones. The expression cassette of pIRESneo contains the human cytomegalovirus (CMV) major immediate early promoter/enhancer followed by a multiple cloning site (MCS), a synthetic intron known to enhance the stability of the mRNA (4), the ECMV IRES followed by the neomycin phosphotransferase (NPT II) gene, and the polyadenylation signal of the bovine growth hormone. Ribosomes can enter the bicistronic mRNA either at the 5' end to translate the gene of interest or at the ECMV IRES to translate the antibiotic resistance marker.

应用

When using the pIRESneo Vector, the antibiotic exerts selective pressure on the whole expression cassette; thus, a high dose of antibiotic will select only cells expressing a high level of the gene of interest. This selective pressure also ensures that the expression of the gene of interest will be stable over time in culture. Unless your expression experiments require a pure population of cells, you can use the pool of cells surviving selection instead of isolating and characterizing clonal cell lines. We recommend selecting mammalian cultures in 500–1,300 mg/ml of G418 (#8056-1) depending on the cell line (be sure to establish a kill curve for each lot of G418 to determine optimal selection

关于我们 About Us

公司简介

基因搜项目发展历程最早可追溯至2010年01月05日域名注册,项目发起即为促进基因资源共享,避免在基因研究工作中“重复造轮子”,节约广大科研精英的宝贵时间和精力。


让基因研究更简单!


您值得信赖的一站式基因研究合作伙伴!

联系我们